Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
Rhea-AI Summary
Amarin (NASDAQ: AMRN) will report first quarter 2026 financial results and host a conference call on Wednesday, April 29, 2026.
The company will release results in pre-market hours and hold a live call at 8:00 a.m. ET, with telephone dial-in, webcast access on the Investor Relations website, and a replay available online until 10/29/26.
Positive
- None.
Negative
- None.
News Market Reaction – AMRN
In the Apr 15 session, AMRN gained 4.47%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.5x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Earnings date notice | Neutral | +0.6% | Set timing for Q4 and full-year 2025 results and call logistics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The last earnings-date announcement with the same tag saw a modestly positive 0.6% move, hinting that simple scheduling updates have historically had limited price impact.
Recent news flow has focused on cardiovascular outcomes data and guideline support for icosapent ethyl, alongside restructuring and cost controls. The current release simply schedules Q1 2026 results and a conference call, similar to the Feb 11, 2026 notice for Q4 and full‑year 2025. That prior scheduling update coincided with a modest 0.6% gain, reinforcing that such announcements mainly frame timing rather than introduce new fundamentals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.
Information on how to participate is as follows.
Access to the live call:
Via telephone: Dial in within the United States: 888-506-0062
International dial in: 973-528-0011
Access Code: 543818
Via online: A webcast of the call will be available on the Investor Relations section of the Company's website at www.amarincorp.com.
Access to the replay:
Via telephone: Dial in within the United States: 877-481-4010
International dial in: 919-882-2331
Replay Code: 53836
Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company's website at www.amarincorp.com, beginning shortly after the end of the live call and available until 10/29/26.
About Amarin
Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Media Inquiries:
Tegan Berry
Amarin Corporation plc
PR@amarincorp.com
Investor Inquiries:
Devin Sullivan & Conor Rodriguez
The Equity Group on Behalf of Amarin
dsullivan@theequitygroup.com or crodriguez@theequitygroup.com
Investor.relations@amarincorp.com
